Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 326 participants.

Also called NCT07034690

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 326 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07034690
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Arab Emirates (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07034690. Randomized; no masking; primary purpose other. Start 2025-11-26 (actual); primary completion 2027-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
Acronym
OPTIMA
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Other)
Educational Material
Intervention (Other)
Standard of care
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07034690
Content hash
b58660518cf192c739ca213e810936d85e71fa2ff0906a02d3b6fd83013f3c63